A Phase 1 interventional study of autologous decidual-like NK cells in Abortion, Habitual, Infertility Unexplained and Embryo Implantation, sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. Recruiting at 1 site in China. Open to female participants aged 22 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-11-17.
Sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Abortion, Habitual with a site in China — 4 open to participants now, 4 under way, 1 of them phase 3. Abortion, Habitual · China.
Among the 14 studies in Abortion, Habitual with a site in China, this one is one of 2 that started in 2025, is the only one in phase 1, and was the 13th registered.
102 studies on the registry are indexed under Abortion, Habitual; 21 are open to participants now.
Browse Abortion, Habitual studies →4 of the 14 studies in Abortion, Habitual with a site in China are open now. Recruiting first, the newest first:
Westlake University · Sites in China
Ages 18–40 · Women only
Women's Hospital School Of Medicine Zhejiang University · Sites in China
Ages 18–40 · Women only
RenJi Hospital · Sites in China
Ages 20–50 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 15 Abortion, Habitual studies recruiting now, 3 (20%) set no upper age limit and 12 (80%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: 22 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 2 · Phase 4 1
First in 2014; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 14 is below the median of 126 across 55 interventional studies indexed under Abortion, Habitual.
Median enrollment 246 across the 6 interventional studies, 214 across the 8 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 14 has an industry lead sponsor. The 10 most frequent:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School is the lead sponsor of 251 studies on the registry; 148 are open to participants now.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School has 1 study filed under Abortion, Habitual — fewer than ten, so there is no comparison to draw.
2 of the studies in Abortion, Habitual with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06999278Phase 3Women's Hospital School Of Medicine Zhejiang UniversityLIGHT Trial: Levothyroxine for Gestational Hypothyroidism in Recurrent Pregnancy Loss | 2027-04-30 |
| NCT06821685The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolAutologous Decidual-like Natural Killer Cells Therapy for Infertility or Adverse Pregnancy History | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Abortion, Habitual with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is preliminary exploration of the effectiveness and duration of autologous decidual-like NK cells therapy in improving uterine NK cells dysfunction.
Menstrual blood analysis will be performed on patients with infertility or a history of adverse pregnancy outcomes who have fertility needs. Those with abnormal uterine NK cells function will be screened and given informed consent forms pre-treatment. Collecting peripheral blood from the patients, isolating and inducing in vitro culture to obtain autologous decidual like NK cells which will be perfused into their uterine. Perform continuous menstrual blood analysis within 6 months after the first treatment to assess the improvement of uterine NK cell function. If the function of uterine NK cells improves, enter the stage of attempting pregnancy and follow up pregnancy outcomes; If the function of uterine NK cells does not improve, then autologous decidual like NK cells uterine cavity perfusion therapy will be performed again. NK cells intrauterine infusion will be treated up to 2 times.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autologous decidual like NK cells will be isolated and induced in vitro culture from the patients' peripheral blood and perfused into their uterine.
Biological: autologous decidual-like NK cells
intrauterine infusion
Improvement rate of NK cells
Improvement rate of NK cells in menstrual blood of patients after intrauterine infusion of autologous decidual like NK cells
Time frame: 6 months after the first intrauterine infusion therapy
Duration of improvement in NK cells
Duration of improvement in NK cells in menstrual blood of patients after intrauterine infusion of autologous decidual like NK cells
Time frame: 6 months after the first intrauterine infusion therapy
Clinical pregnancy
Ultrasound indicates the presence of a gestational sac and fetal heartbeat in the uterine cavity
Time frame: 1 year after completion of NK cells therapy
Ongoing pregnancy
At least 12 weeks of pregnancy, ultrasound indicates that the fetus has cardiac activity and the size of the fetus matches the gestational age
Time frame: 1 year after completion of NK cells therapy
Live birth
Delivery of any number of neonates born at 26 or more weeks' gestation with signs of life
Time frame: 1 year after completion of NK cells therapy
preeclampsia
The occurrence of preeclampsia during successful ongoing pregnancy after cell therapy
Time frame: 1 year after completion of NK cells therapy
fetal growth restriction
The occurrence of fetal growth restriction during successful ongoing pregnancy after cell therapy
Time frame: 1 year after completion of NK cells therapy
Started Feb 2025 (actual). Primary completion is estimated for Jul 2027, 29 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School →